Breakthrough No Guarantee Of Success
This article was originally published in The Pink Sheet Daily
Executive Summary
Though CEO called the BTD a "godsend," the program didn't prevent an RTF action.
You may also be interested in...
Keeping Track: US FDA Enters Year's Final Stretch With Tsunami Of Novel Approvals
The latest drug development news and highlights from our US FDA Performance Tracker.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Rare Disease Roundtable: How Rare Is Too Rare?
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.